[Sharp syndrome complicating pulmonary tuberculosis: apropos of a case].
This study concerns a case-report about a 28 year old Senegalese woman suffering from a SHARP syndrome complicated by a bilateral bacillary pulmonary tuberculosis. The prevalence of this disease is underestimated but a female predominance is often reported. The mechanisms of this disease strongly depends upon the context in with it occurs. The diagnostic has been established by the ALARCON SEGOVIA criteria including clinical symptoms (Raynaud phenomenon, puffy fingers and myalgia) and biological features such as high positive immunofluorescent reactivity revealing the presence of anti RNP antibody at a level superior to 1/1000. The subsequent development figure of the disease emphasizes: persistence of polymyositis pattern revealed by higher limbs localized myalgia involving the thighs and symptoms of lupus including alopecia and glomerulonephritis remaining of the mixed characteristic comparable to the cases published in the literature. appearance of a bilateral bacillary pulmonary tuberculosis with a severe involvement of the right lung. The treatment composed by anti inflammatory and antituberculosis drugs lead to an early improvement of the clinical symptoms associated to a rapid cleaning of radiological manifestations. Sequelae were represented by cavities detected in the right lung and related to the pharmacological effects of corticosteroid drugs.
Ndiaye
M
M
Service de Pneumophtisiologie C.H.U. de FANN BP: 5035 Dakar/Fann.
Hane
A A
AA
Dieng
M T
MT
Ndir
M
M
Ba
O
O
Cissokho
S
S
Kandji
M
M
Diatta
A
A
Niang
A
A
Ndiaye
B
B
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D000995:Antitubercular Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D008947:Mixed Connective Tissue Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D011718:Pyrazinamide / Q000627:therapeutic use; D012261:Ribonucleoproteins / Q000276:immunology*; D013307:Streptomycin / Q000627:therapeutic use; D013577:Syndrome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy; D025101:Vitamin B 6 / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000974:Antibodies, Antinuclear; D000995:Antitubercular Agents; D012261:Ribonucleoproteins; D011718:Pyrazinamide; D025101:Vitamin B 6; D013307:Streptomycin